Physiological regulation of the pancreatic β-cell: Functional insights for understanding and therapy of diabetes

Experimental Physiology

Volumn 92, Issue 3, 2007, Pages 481-496

  McClenaghan, Neville H ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; HOMOCYSTEINE; NATEGLINIDE; TOLBUTAMIDE;

BIOENGINEERING; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINE; CELL STRAIN BRIN BD11; CONFERENCE PAPER; DESENSITIZATION; DIABETES MELLITUS; ELECTROFUSION (CELL); EMBRYONIC STEM CELL; GENE EXPRESSION; HUMAN; HYBRID CELL; HYPERGLYCEMIA; INSULIN RELEASE; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE; NUTRIENT; PANCREAS ISLET BETA CELL; SIGNAL TRANSDUCTION;

EID: 34247259818     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2006.034835     Document Type: Conference Paper

References (56)

1. Bai L, Meredith G & Tuch BE (2005). Glucagon-like peptide-1 enhances production of insulin-producing cells derived from mouse embryonic stem cells. J Endocrinol 186, 343-352.
2. Ball AJ, Flatt PR & McClenaghan NH (2000a). Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide. Eur J Pharmacol 408, 327-333.
3. Ball AJ, Flatt PR & McClenaghan NH (2004a). Acute and long-term effects of nateglinide on insulin secretory pathways. Br J Pharmacol 142, 367-373.
4. Ball AJ, Flatt PR & McClenaghan NH (2005). Alterations of insulin secretion following long-term manipulation of ATP-sensitive potassium channels by diazoxide and nateglinide. Biochem Pharmacol 69, 59-63.
5. Ball AJ, McCluskey JT, Flatt PR & McClenaghan NH (2000b). Drug-induced desensitization of insulinotropic actions of sulfonylureas. Biochem Biophys Res Commun 271, 234-239.
6. Ball AJ, McCluskey JT, Flatt PR & McClenaghan NH (2004b). Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not expression of K-ATP channel components. Pharmac Res 50, 41-46.
7. Bonner-Weir S & Weir GC (2005). New sources of pancreatic β-cells. Nat Biotechnol 23, 857-861.
8. 13C NMR analysis reveals a link between L-glutamine metabolism, D-glucose metabolism and γ-glutamyl cycle activity in a clonal pancreatic β-cell line. Diabetologia 46, 1512-1521.
9. Brennan L, Shine A, Hewage C, Malthouse JPG, Brindle KM, McClenaghan NH, Flatt PR & Newsholme P (2002). A NMR based demonstration of substantial oxidative L-alanine metabolism and L-alanine enhanced glucose metabolism in a clonal pancreatic β cell line - Metabolism of L-alanine is important to the regulation of insulin secretion. Diabetes 51, 1714-1721.
10. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren P-O & Caicedo A (2006). The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A 103, 2334-2339.
11. Chapman JC, McClenaghan NH, Cosgrove KE, Hashmi MN, Shepherd RM, Giesberts AN, White SJ, Ammala C, Flatt PR & Dunne MJ (1999). ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 β-cell line. Diabetes 48, 2349-2357.
12. 2+ levels after incubation in the presence of newly diagnosed Type-1 diabetic patient sera. Possible role in serum-induced inhibition of insulin secretion. J Endocrinol 173, 53-62.
13. Corless M, Kiely A, McClenaghan NH, Flatt PR & Newsholme P (2006). Glutamine regulates expression of key transcription factor, signal transduction, metabolic gene and protein expression in a clonal pancreatic β cell line. J Endocrinol 190, 719-727.
14. Cunningham G, McClenaghan NH, Flatt PR & Newsholme P (2005). L-Alanine induces changes in metabolic and signal transduction gene expression in a clonal rat pancreatic β-cell line and protects from pro-inflammatory cytokine-induced apoptosis. Clin Sci 109, 447-455.
15. Davies EL, Abdel-Wahab YHA, Flatt PR & Bailey CJ (2001). Functional enhancement of electrofusion-derived BRIN-BD11 insulin-secreting cells after implantation into diabetic mice. Int J Exp Diabetes Res 2, 29-36.
16. Dixon G, Nolan J, McClenaghan NH, Flatt PR & Newsholme P (2003). A comparative study of amino acid consumption by rat islet cells and the clonal β-cell line BRIN BD11 - the functional significance of L-alanine. J Endocrinol 179, 447-453.
17. Dixon G, Nolan J, McClenaghan NH, Flatt PR & Newsholme P (2004). Arachidonic acid, palmitic acid and glucose are important for the modulation of clonal β cell insulin secretion, growth and functional integrity. Clin Sci 106, 191-199.
18. 2+ concentration. J Biol Chem 273, 33501-33507.
19. Eliasson L, Ma X, Renstrom E, Barg S, Berggren P-O, Galvanovskis J, Gromada J, Jing X, Lundquist I, Salehi A, Sewing S & Rorsman P (2003). SUR1 regulates PKA-dependent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 121, 181-187.
20. Flatt PR & Lenzen S (eds) (2004). Frontiers of Insulin Secretion and Pancreatic β-cell Research. Smith-Gordon, London.
21. Gault VA, Flatt PR & O'Harte FPM (2003). Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 308, 207-213.
22. Green BD, Gault VA, O'Harte FPM & Flatt PR (2004). Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 10, 3651-3562.
23. Hamid M, McCluskey JT, McClenaghan NH & Flatt PR (2000). Culture and function of electrofusion-derived clonal insulin-secreting cells immobilised on solid and macroporous microcarrier beads. Biosci Rep 20, 167-176.
24. Hamid M, McCluskey JT, McClenaghan NH & Flatt PR (2001). Functional examination of microencapsulated clonal insulin-secreting β cells. Cell Biol Int 25, 553-556.
25. Karam JH, Sanz E, Solomon E & Nolte MS (1986). Selective unresponsiveness of pancreatic B-cells to acute sulphonylurea stimulation during sulphonylurea therapy in NIDDM. Diabetes 35, 1314-1320.
26. Keller G (2005). Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev 19, 1129-1155.
27. Liu H-K, Green BD, Gault VA, McClenaghan NH, McCluskey JT & Flatt PR (2004). N-Acetyl-GLP-1: a DPP IV resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic β-cell associated gene expression. Cell Biol Int 28, 69-73.
28. Liu H-K, Green BD, McClenaghan NH, McCluskey JT & Flatt PR (2006). Deleterious effects of dehydroepiandrosterone sulphate and dexamethasone on rat insulin-secreting cells under in vitro culture condition. Biosci Rep 26, 31-38.
29. Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R & McKay R (2001). Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 292, 1389-1394.
30. McClenaghan NH (2005). Determining the relationship between dietary carbohydrate intake and insulin resistance. Nut Res Rev 18, 222-240.
31. McClenaghan NH, Ball AJ & Flatt PR (2000). Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide. Br J Pharmacol 130, 478-484.
32. McClenaghan NH, Ball AJ & Flatt PR (2001). Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure. Biochem Pharmacol 61, 527-536.
33. McClenaghan NH, Barnett CR, Ah-Sing E, Yoon TW, Abdel-Wahab YHA, Swanston-Flatt SK & Flatt PR (1996a). Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45, 1132-1140.
34. + co-transport by metabolizable and non-metabolizable amino acids stimulates a glucose-regulated insulin-secretory response. Biochem Biophys Res Comm 249, 299-303.
35. McClenaghan NH, Barnett CR, O'Harte FPM & Flatt PR (1996b). Mechanisms of amino acid-induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line. J Endocrinol 151, 349-357.
36. McClenaghan NH, Barnett CR, O'Harte FPM, Swanston-Flatt SK, Ah-Sing E & Flatt PR (1996c). Characteristics of BRIN-BG5 and BRIN-BG7, two novel glucose-responsive insulin-secreting cell lines produced by electrofusion. J Endocrinol 148, 409-417.
37. +. Pancreas 14, 65-70.
38. McClenaghan NH, Elsner M, Tiedge M & Lenzen S (1998b). Molecular characterization of the glucose-sensing mechanism in the clonal insulin-secreting BRIN-BD11 cell line. Biochem Biophys Res Commun 242, 262-266.
39. McClenaghan NH & Flatt PR (1999a). Engineering cultured insulin-secreting pancreatic B-cell lines. J Mol Med 77, 235-243.
40. McClenaghan NH & Flatt PR (1999b). Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diabetes Obes Metab 1, 137-150.
41. McClenaghan NH & Flatt PR (1999c). Glucose and non-glucidic nutrients exert permissive effects on 2-keto acid regulation of pancreatic β cell function. Biochim Biophys Acta 426, 110-118.
42. +-ATP channel independent actions of keto acid initiators of insulin secretion. Pancreas 20, 38-46.
43. McClenaghan NH & Flatt PR (2003). Hormones of the endocrine pancreas. In Encyclopaedia of Food Science and Nutrition, 2nd edn, ed. Caballero B, Trugo L & Finglas P, pp. 3150-3157. Academic Press, London.
44. McClenaghan NH, Gray AM, Barnett CR & Flatt PR (1996d). Hexose recognition by insulin-secreting BRIN-BD11 cells. Biochem Biophys Res Commun 223, 724-728.
45. Madsen OD (2005). Stem cells and diabetes treatment. APMIS 113, 858-875.
46. 16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biol Chem 387, 941-947.
47. Patterson S, Flatt PR, Brennan L, Newsholme P & Mc Clenaghan NH (2006). Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic beta-cell glucose metabolism and insulin secretion. J Endocrinol 189, 301-310.
48. Pickup JC & Williams G (2003). The Textbook of Diabetes, 3rd edn. Blackwell Science, Oxford.
49. Picton S, McCluskey JT, Flatt PR & McClenaghan NH (2002). Effects of cytotoxic agents on functional integrity and antioxidant enzymes in clonal β cells. Diabetes Metab 28, 3S70-3S77.
50. Prentki M, Joly E, El-Assaad W & Roduit R (2002). Malonyl-CoA signalling, lipid partitioning, and glucolipotoxicity. Role in β-cell adaption and failure in the etiology of diabetes. Diabetes 51 (Suppl. 3), S405-S413.
51. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM & Rajotte RV (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343, 230-238.
52. + channel: a pas de deux. Diabetes 53 (Suppl. 3), S113-S122.
53. 2+ oscillations into a sustained increase parallels potentiation of insulin release. Biochem Biophys Acta 1137, 243-247.
54. Tiedge M, Elsner M, McClenaghan NH, Hedrich HJ, Grube D, Klempnauer J & Lenzen S (2000). Correction of diabetic hyperglycaemia by transplantation of bioengineered RINm5F cells overexpressing pancreatic β-cell glucokinase. Hum Gene Ther 11, 403-414.
55. Wiederkehr A & Wollheim CB (2006). Minireview: Implication of mitochondria in insulin secretion and action. Endocrinology 147, 2643-2649.
56. Zimmermann U (1986). Electrical breakdown, electro-permeabilization and electrofusion. Rev Physiol Biochem Pharmacol 105, 176-250.